More efficient mobilisation of peripheral blood stem cells with HiDAC plus AMSA plus G-CSF than with mini-ICE plus G-CSF in patients with AML
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift
We have compared the efficacy of two PBSC mobilisation regimens, mini-ICE + filgrastim (second consolidation) and HiDAC + AMSA + filgrastim (third consolidation), in two consecutive cohorts of patients with AML CR1 receiving treatment according to a joint protocol. Group A: 18 patients, aged 41 (21-65) years, were mobilised with mini-ICE (idarubicin 8 mg/m(2) + cytarabine 800 mg/m(2) + etoposide 150 mg/m(2) days 1-3) followed by filgrastim 300-480 mug once daily s.c. from day 11 after start of chemotherapy. Only four patients reached >5 CD34+ cells/mul blood (B-CD34+) and were able to undergo leukaphereses. Two out of 18 (11%) reached the defined target of greater than or equal to2.0 x 10(6) CD34+ cells/kg after 1-3 leukaphereses. Group B: 20 patients, aged 50 (29-67) years, received HiDAC + AMSA (cytarabine 3 g/m(2) b.i.d. days 1, 3, 5 + amsacrine 150 mg/m(2) q.d. days 2, 4) followed by filgrastim at a similar dose starting on day 7. A total of 18 patients reached B-CD34+ >5/mul and underwent PBSC harvesting, starting on day 23 (14-29) and yielding 4.0 (0.9-21) x 10(6) CD34+ cells/kg. Of 20 patients, 17 (85%) reached the defined target of greater than or equal to2.0 x 10(6) CD34+ cells/kg after 1-3 leukaphereses. We conclude that wHiDAC + AMSA + G-CSF - in contrast to mini-ICE + G-CSF - is an efficient regimen for mobilising PBSC in patients with AML CR1.
Ämnesklassifikation (UKÄ) – OBLIGATORISK
|Tidskrift||Bone Marrow Transplantation|
|Status||Published - 2003|
|Peer review utförd||Ja|